REHABILITATION INSTITUTE OF CHICAGO

Their core work

The Rehabilitation Institute of Chicago (RIC) is a US-based clinical and translational research center focused on restoring movement and function in people with severe neurological injuries, including spinal cord injury and tetraplegia. Their H2020 contributions center on neural engineering: implantable devices that record and stimulate neural tissue, and brain-neural computer interfaces (BNCI) that allow the nervous system to communicate bidirectionally with external technology. In the EU context, RIC functions as a high-value clinical partner — a US institution with deep patient populations and rehabilitation infrastructure that European neurotechnology consortia cannot easily replicate domestically. Their participation in EU projects typically occurs through MSCA Global Fellowships, where researchers move between RIC and European labs to transfer methodologies across the Atlantic.

What they specialise in

How they've shifted over time

Both H2020 projects were launched in the same year (2018), so there is no meaningful temporal shift to read from the timeline. The keyword-rich project (EXTEND) focuses on the technology layer — neural interfaces, recording, stimulation, BNCI — while the second project (REBoT) sits closer to the clinical application layer, targeting functional recovery after tetraplegia. This pairing suggests RIC spans both ends of the translational pipeline: building and validating neural devices (EXTEND) and applying them toward patient rehabilitation outcomes (REBoT). Without projects from a later period, it is not possible to determine whether their EU engagement deepened, narrowed, or shifted direction after 2018.

RIC's EU footprint is too small (2 projects, same start year) to read a directional trend — but their dual presence in both a neural engineering RIA and an MSCA Global Fellowship suggests they are positioning as a transatlantic clinical validation site for European neurotechnology teams.

How they like to work

RIC has never led an H2020 project — both participations are as partner or third party, which is typical for US institutions in EU-funded research where coordination roles are restricted to EU/associated countries. They work within mid-sized consortia (9 unique partners) and bring clinical and translational expertise that European partners lack rather than driving the technical agenda. Their MSCA-IF-GF involvement also signals openness to hosting individual researchers, making them accessible for bilateral knowledge exchange outside full consortium commitments.

RIC has connected with 9 unique partners across 5 countries through its H2020 participation — a modest but geographically distributed network for a US institution. As a non-EU partner, their reach into European neurotechnology and rehabilitation research networks is notable, though still early-stage given only two projects.

What sets them apart

RIC is one of very few US clinical rehabilitation centres active in the H2020 ecosystem, which makes them unusual and strategically valuable: European consortia working on neural prosthetics or motor rehabilitation can access US-scale patient cohorts and a world-class rehabilitation clinical infrastructure that is difficult to find within the EU. Their positioning at the intersection of implantable neurotechnology and clinical rehabilitation — rather than purely basic neuroscience or purely medical devices — fills a translational gap that many tech-heavy EU consortia struggle to cover internally.

Highlights from their portfolio

• EXTEND
  A full RIA project on bidirectional neural systems (2018–2022), where RIC's participant role placed them at the core of the technical consortium building implantable neural interfaces — the most technology-intensive engagement in their H2020 record.
• REBoT
  An MSCA Global Fellowship project targeting tetraplegia recovery (2018–2021) that illustrates RIC's role as a transatlantic host institution, enabling EU researchers to train in US clinical rehabilitation environments and bring methods back to Europe.